[go: up one dir, main page]

UA90708C2 - Таблетки с улучшенной дисперсностью лекарственного вещества - Google Patents

Таблетки с улучшенной дисперсностью лекарственного вещества

Info

Publication number
UA90708C2
UA90708C2 UAA200710576A UAA200710576A UA90708C2 UA 90708 C2 UA90708 C2 UA 90708C2 UA A200710576 A UAA200710576 A UA A200710576A UA A200710576 A UAA200710576 A UA A200710576A UA 90708 C2 UA90708 C2 UA 90708C2
Authority
UA
Ukraine
Prior art keywords
drug substance
tablets
improved drug
carrier
dispersibility
Prior art date
Application number
UAA200710576A
Other languages
English (en)
Ukrainian (uk)
Inventor
Натали Бернигаль
Эрик Гарсиа
Сюзанне Паге
Жозеф Тардио
Original Assignee
Ф. Хоффманн-Ля Рош Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36406213&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA90708(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ф. Хоффманн-Ля Рош Аг filed Critical Ф. Хоффманн-Ля Рош Аг
Publication of UA90708C2 publication Critical patent/UA90708C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Изобретение относится к способу получения фармацевтических композиций в форме таблеток с улучшенной дисперсностью лекарственного вещества и с лекарственным веществом, отобранным из группы BCS класса II или IV, которое содержится в таблетке в массовом процентном отношении от 25 до 70 % массы таблетки, который включает стадии, на которых:а) получают дисперсию по меньшей мере одного фармацевтически активного лекарственного вещества и по меньшей мере одного поверхностно-активного вещества и/или связующего вещества в жидкости;б) получают носитель в ходе сухого смешивания наполнителей и/или дезинтегрирующих агентов и пористого носителя, где пористый носитель является коллоидным диоксидом кремния; ив) распылением гранулируют дисперсию, полученную согласно а), на носитель, полученный согласно б), чтобы получить гранулированный распылением продукт.
UAA200710576A 2005-02-25 2006-02-16 Таблетки с улучшенной дисперсностью лекарственного вещества UA90708C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05101458 2005-02-25

Publications (1)

Publication Number Publication Date
UA90708C2 true UA90708C2 (ru) 2010-05-25

Family

ID=36406213

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200710576A UA90708C2 (ru) 2005-02-25 2006-02-16 Таблетки с улучшенной дисперсностью лекарственного вещества

Country Status (20)

Country Link
US (2) US20060193910A1 (ru)
EP (2) EP2281556A1 (ru)
JP (1) JP2008531509A (ru)
KR (1) KR20070094666A (ru)
CN (1) CN101128189A (ru)
AR (1) AR055561A1 (ru)
AU (1) AU2006218193A1 (ru)
BR (1) BRPI0606187A2 (ru)
CA (1) CA2598762A1 (ru)
CR (1) CR9292A (ru)
IL (1) IL185011A0 (ru)
MA (1) MA29268B1 (ru)
MX (1) MX2007009571A (ru)
NO (1) NO20074092L (ru)
NZ (1) NZ560232A (ru)
RU (1) RU2007129642A (ru)
TW (1) TW200640502A (ru)
UA (1) UA90708C2 (ru)
WO (1) WO2006089674A2 (ru)
ZA (1) ZA200706495B (ru)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
GB0123400D0 (en) 2001-09-28 2001-11-21 Novartis Ag Organic compounds
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
WO2007122635A2 (en) * 2006-04-26 2007-11-01 Astron Research Limited Controlled release formulation comprising anti-epileptic drugs
US20100055180A1 (en) * 2007-10-10 2010-03-04 Mallinckrodt Baker, Inc. Directly Compressible Granular Microcrystalline Cellulose Based Excipient, Manufacturing Process and Use Thereof
KR101633939B1 (ko) * 2007-10-10 2016-06-27 아반토르 퍼포먼스 머티리얼스, 인크. 직접 압축성 고기능성 과립 미세결정 셀룰로스계 부형제, 그의 제조 방법 및 용도
DE102008047910A1 (de) 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co. Kg Tablettierhilfsstoff auf Laktose- und Cellulosebasis
KR20140002812A (ko) * 2009-01-23 2014-01-08 에프. 호프만-라 로슈 아게 알레글리타자르를 포함하는 약학 조성물
RS53491B1 (sr) 2009-11-18 2015-02-27 Helsinn Healthcare Sa Kompozicije za lečenje centralno posredovane mučnine i povraćanja
EP2722045B1 (en) 2009-11-18 2016-07-06 Helsinn Healthcare SA Compositions for treating centrally mediated nausea and vomiting
CN102641302B (zh) * 2011-02-18 2016-01-20 上海张江中药现代制剂技术工程研究中心 一种提高中药提取物浸膏粉软化点的方法
RU2468789C1 (ru) * 2011-05-04 2012-12-10 Федеральное государственное бюджетное учреждение науки Иркутский институт химии им. А.Е. Фаворского Сибирского отделения Российской академии наук (ИрИХ СО РАН) Средство для профилактики и лечения атеросклероза
CN104784239B (zh) * 2015-04-28 2017-12-26 新乡医学院第一附属医院 一种快速溶出的珍菊降压片及其制备工艺
WO2017003137A1 (ko) * 2015-06-30 2017-01-05 (주)아모레퍼시픽 속붕해형 과립환 모발 세정용 조성물
KR20170003414A (ko) * 2015-06-30 2017-01-09 (주)아모레퍼시픽 속붕해형 과립환 모발 세정용 조성물
BR112019010003A2 (pt) 2016-11-16 2019-08-20 Abide Therapeutics Inc formas cristalinas de um inibidor de magl
CA3043609A1 (en) * 2016-11-16 2018-05-24 Abide Therapeutics, Inc. Pharmaceutical formulations
CN109701441B (zh) * 2018-12-16 2021-04-09 桂林理工大学 一种卵磷脂选择性改性高岭石的制备方法及其应用
TWI728709B (zh) * 2020-02-19 2021-05-21 台灣森本生物科技開發股份有限公司 含有得自於藤黃樹脂的丙酮萃取產物的藥學組成物以及由該組成物所製得的配方
CN111548218A (zh) * 2020-04-27 2020-08-18 上海应用技术大学 一种通用型花肥速释片及其制备方法和应用
CN116602928A (zh) * 2023-06-30 2023-08-18 康普药业股份有限公司 一种甲苯磺酸艾多沙班组合物和制备方法
US12296050B2 (en) * 2023-10-05 2025-05-13 Mirum Pharmaceuticals, Inc. Pharmaceutical compositions comprising maralixibat and uses thereof
CN119857081B (zh) * 2025-01-16 2025-10-17 江苏亚邦爱普森药业有限公司 一种乌帕替尼缓释片及其制备方法

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE77165B1 (en) * 1991-01-30 1997-12-03 Wellcome Found Water-dispersible tablet containing acyclovir
EP0919245A3 (en) 1991-09-20 2000-11-15 Glaxo Group Limited NK-1 receptor antagonist and a systemic antiinflammatory corticosteroid for the treatment of emesis
KR100384264B1 (ko) * 1994-09-22 2003-08-30 악조 노벨 엔.브이. 습식과립화에의한 투여단위의제조방법
US6106865A (en) * 1995-01-09 2000-08-22 Edward Mendell Co., Inc. Pharmaceutical excipient having improved compressibility
IT1276160B1 (it) * 1995-11-22 1997-10-27 Recordati Chem Pharm Composizioni farmaceutiche orali a pronto rilascio per sospensioni estemporanee
DE69732133T2 (de) 1996-12-02 2005-12-22 Merck Sharp & Dohme Ltd., Hoddesdon Verwendung von NK-1 Rezeptorantagonisten zur Behandlung von schweren Depressionen
ATE288756T1 (de) 1996-12-02 2005-02-15 Merck Sharp & Dohme Verwendung von nk-1 rezeptorantagonisten zur behandlung von schweren depressionen, die von angstzuständen begleitet werden
FR2758459B1 (fr) * 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
JP4367723B2 (ja) * 1997-08-25 2009-11-18 大正製薬株式会社 水難溶性成分を配合した固形剤
GB9825242D0 (en) 1998-11-19 1999-01-13 Cambridge Advanced Tech Genetically modified plants with altered starch
PE20001302A1 (es) * 1998-11-27 2000-11-30 Hoffmann La Roche Preparaciones de una combinacion farmaceutica que contiene carvedilol e hidroclorotiazida
HRP20010603A2 (en) 1999-02-24 2002-08-31 Hoffmann La Roche Phenyl-and pyridinyl derivatives
HUP0200139A3 (en) 1999-02-24 2003-01-28 Hoffmann La Roche 3-phenylpyridine derivatives and their use as nk-1 receptor antagonists, process for their preparation and pharmaceutical compositions containing them
EP1035115B1 (en) 1999-02-24 2004-09-29 F. Hoffmann-La Roche Ag 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists
WO2000053772A1 (en) 1999-03-06 2000-09-14 Roche Diagnostics Gmbh Dna polymerase from pyrobaculum islandicum
JO2308B1 (en) 1999-05-31 2005-09-12 اف. هوفمان- لاروش أيه جي‏ Derivatives of phenylpyrmidine
TW550258B (en) 1999-05-31 2003-09-01 Hoffmann La Roche 4-phenyl-pyrimidine derivatives
US7863331B2 (en) * 1999-07-09 2011-01-04 Ethypharm Pharmaceutical composition containing fenofibrate and method for the preparation thereof
FR2795961B1 (fr) * 1999-07-09 2004-05-28 Ethypharm Lab Prod Ethiques Composition pharmaceutique contenant du fenofibrate micronise, un tensioactif et un derive cellulosique liant et procede de preparation
US6303790B1 (en) 1999-11-29 2001-10-16 Hoffman-La Roche Inc. Process for the preparation of pyridine derivatives
ATE253561T1 (de) 1999-11-29 2003-11-15 Hoffmann La Roche 2-(3,5-bis-trifluoromethyl-phenyl)-n-methyl-n-( - morpholin-4-yl-4-o-tolyl-pyridin-3-yl)- isobutyramid
AUPQ514600A0 (en) 2000-01-18 2000-02-10 James Cook University Brain injury treatment
US6452001B2 (en) 2000-05-25 2002-09-17 Hoffmann-La Roche Inc. Diazapane derivatives useful as antagonists of neurokinin 1 receptor and methods for their formation
US6482829B2 (en) 2000-06-08 2002-11-19 Hoffmann-La Roche Inc. Substituted heterocyclic siprodecane compound active as an antagonist of neurokinin 1 receptor
SI1303490T1 (sl) 2000-07-14 2008-10-31 Hoffmann La Roche N-oksidi kot predzdravila NK 1 receptorskega antagonista 4-fenil-piridin derivatov
TWI287003B (en) 2000-07-24 2007-09-21 Hoffmann La Roche 4-phenyl-pyridine derivatives
TWI259180B (en) 2000-08-08 2006-08-01 Hoffmann La Roche 4-Phenyl-pyridine derivatives
YU39503A (sh) 2000-11-22 2006-05-25 F. Hoffmann-La Roche Ag. Derivati pirimidina
WO2002047663A1 (en) 2000-12-14 2002-06-20 F. Hoffman-La Roche Ag Self emulsifying lipid matrix (selm)
US6642226B2 (en) 2001-02-06 2003-11-04 Hoffman-La Roche Inc. Substituted phenyl-piperidine methanone compounds
US6531597B2 (en) 2001-02-13 2003-03-11 Hoffmann-La Roche Inc. Process for preparation of 2-phenyl acetic acid derivatives
MXPA03009720A (es) 2001-04-23 2004-01-29 Hoffmann La Roche USO DE ANTAGONISTAS DEL RECEPTOR DE NK-1 PARA TRATAMIENTO O PREVENCIoN DE HIPERPLASIA PROSTATICA BENIGNA.
BR0209604A (pt) 2001-05-14 2004-03-23 Hoffmann La Roche Derivados de 1-oxa-3,9-diaza-spiro-5,5-undecan-2-onas e seu uso como antagonista do receptor para neuricinina
US20030083345A1 (en) 2001-07-10 2003-05-01 Torsten Hoffmann Method of treatment and/or prevention of brain, spinal or nerve injury
US6849624B2 (en) 2001-07-31 2005-02-01 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted amides
US6667327B2 (en) 2002-02-04 2003-12-23 Hoffmann-La Roche Inc. Pyridine amido derivatives
US6660736B2 (en) 2002-03-27 2003-12-09 Hoffmann-La Roche Inc. Phthalimido derivatives and a process for their preparation
CA2483461C (en) 2002-04-26 2010-12-21 F. Hoffmann-La Roche Ag Isoquinoline derivatives
MXPA04011594A (es) 2002-05-29 2005-03-07 Hoffmann La Roche Derivados n-acilaminobenceno como inhibidores selectivos de monoamino oxidasa b.
KR20030095600A (ko) * 2002-06-12 2003-12-24 환인제약 주식회사 펠로디핀을 포함하는 제어방출형 조성물 및 그 제조방법
US6951884B2 (en) 2002-06-12 2005-10-04 Hoffmann-La Roche Inc. Fluorobenzamides and uses thereof
US6900354B2 (en) 2002-07-15 2005-05-31 Hoffman-La Roche Inc. 3-phenyl-propionamido, 3-phenyl-acrylamido and 3-phenyl-propynamido derivatives
US6846832B2 (en) 2002-08-07 2005-01-25 Hoffman-La Roche Inc. 2,3-dihydro-isoindol-1-one derivatives
PE20050077A1 (es) 2002-09-20 2005-03-01 Hoffmann La Roche Derivados de 4-pirrolidino-fenil-bencil-eter
JP2006056781A (ja) * 2002-11-15 2006-03-02 Bioserentack Co Ltd 界面活性剤を含む固形化製剤
DE60307512T2 (de) 2002-12-13 2007-02-08 F. Hoffmann-La Roche Ag 3h-chinazoline -4-on derivaten
NZ541243A (en) 2003-01-31 2008-04-30 Hoffmann La Roche New crystalline modification of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(1,1-dioxo-1lambda6-thiomorpholin-4-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
FR2851918B1 (fr) * 2003-03-06 2006-06-16 Poudre impregnee ameliorant la biodisponibilite et/ou la solubilite et procede de fabrication
US20060068010A1 (en) * 2004-09-30 2006-03-30 Stephen Turner Method for improving the bioavailability of orally delivered therapeutics

Also Published As

Publication number Publication date
JP2008531509A (ja) 2008-08-14
CA2598762A1 (en) 2006-08-31
CN101128189A (zh) 2008-02-20
KR20070094666A (ko) 2007-09-20
BRPI0606187A2 (pt) 2009-06-09
ZA200706495B (en) 2008-10-29
AU2006218193A1 (en) 2006-08-31
NZ560232A (en) 2010-11-26
EP1855655A2 (en) 2007-11-21
MA29268B1 (fr) 2008-02-01
WO2006089674A3 (en) 2007-02-08
US20060193910A1 (en) 2006-08-31
IL185011A0 (en) 2007-12-03
RU2007129642A (ru) 2009-03-27
NO20074092L (no) 2007-09-04
US20090304795A1 (en) 2009-12-10
AR055561A1 (es) 2007-08-22
WO2006089674A2 (en) 2006-08-31
MX2007009571A (es) 2007-09-21
TW200640502A (en) 2006-12-01
CR9292A (es) 2010-04-21
EP2281556A1 (en) 2011-02-09

Similar Documents

Publication Publication Date Title
TW200640502A (en) Tablets with improved drug substance dispersibility
WO2006078593A3 (en) Direct compression formulation and process
TW200711652A (en) Method and composition for pharmaceutical product
WO2008063910A3 (en) Method of preparing solid dosage forms of multi-phasic pharmaceutical compositions
WO2003035051A3 (en) The use of proton sequestering agents in drug formulations
MX2009002757A (es) Formulacion de farmaco resistente al abuso.
WO2008006716A3 (en) Improvements relating to pharmaceutical compositions
WO2002074247A8 (en) Pharmaceutical formulations for sustained release
WO2006011159A3 (en) Stabilized pharmaceutical composition containing rabeprazole sodium with improved bioavailability
UA100866C2 (ru) Продукт твердой дисперсии, который содержит соединения на основе n-арилмочевины
WO2009122301A3 (en) Rasagiline mesylate particles and process for the preparation thereof
WO2009074286A3 (en) Pharmaceutical formulation comprising ezetimibe
EA200900572A1 (ru) Мицеллярные наночастицы с химическими субстанциями
WO2007022255A3 (en) Pharmaceutical formulations for sustained release
WO2010021607A3 (en) Pharmaceutical formulation
WO2008049633A8 (en) Spray-freeze-drying process for the preparation of pellets comprising percolation drying
WO2003082262A3 (en) Compositions of venlafaxine base
WO2008069938A3 (en) Method of forming a tablet comprising pre-blend of ibupropen and silicon dioxide
MX2010004291A (es) Producto de dispersion solida de farmacos basados en n-aril urea.
WO2011056785A3 (en) Microcrystalline cellulose and calcium phosphate compositions useful as pharmaceutical excipients
CN106139156A (zh) 一种含有喹啉衍生物或其盐的药物组合物
GEP20125636B (en) Slow-release formulation based on glycogen and alginate association
TW200621310A (en) A process for preparing formulations of lypophilic active substances by spray freeze drying
WO2008030512A3 (en) Polystyrene sulfonate polymer tablets, their preparation and use
WO2008041073A3 (en) Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof